摘要
上海信谊制药有限公司由上海医药集团有限公司全资控股,是中国化学制药企业中产品最多,剂型最全的产业实体之一,集制造、销售、研发为一体的知名医药企业,旗下拥有十大工业企业、四大销售公司、三家市级研发中心。在保持化学制剂竞争优势的基础上,信谊还确立了微生态、生化制剂在全国的领先地位,并形成粉针剂、气雾剂、眼药水、软胶囊、缓控释制剂五大特色剂型。
The annual output 20 billion tablets preparation and R&D Center is a project jointly built by Shanghai Xine Pharmaceutical Co.,Ltd.and Shandong Fukang Development Holding Group in Shouguang,Shandong province.The project is planned to be constructed in two phases and has progressed smoothly since the contract was signed with Shanghai Pharma in October,2019.After it is completed,the project will have an annual production capacity of 20 billion tablets,the annual sales revenue of 2 billion yuan,and profits and taxes of 500 million yuan.
出处
《走向世界》
2021年第5期62-62,共1页
Openings
